Dr. John P.H. Wilding
Medicine at the University
Biography & Research Background
John P.H. Wilding, DM, FRCP, is a Professor of Medicine at the University of Liverpool and a leading clinical investigator in obesity pharmacotherapy. Dr. Wilding was the lead author on the landmark STEP 1 trial (2021) published in the New England Journal of Medicine, which established once-weekly semaglutide 2.4 mg as one of the most effective pharmacological treatments for obesity, demonstrating a mean 14.9% body weight reduction. He has led or co-authored multiple STEP program publications that transformed the treatment landscape for obesity. John P.H. Wilding is being referenced as one of the leading scientists involved in the research and development of Semaglutide. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. John P.H. Wilding is referenced as a leading researcher in the following peptide research profiles on SHR3D Aminos:
Dr. John P.H. Wilding is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between SHR3D Aminos and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.